Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Status:
Withdrawn
Trial end date:
2017-11-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and how well pembrolizumab and imatinib
mesylate work in treating patients with melanoma with c-KIT mutation or amplification that
has spread to nearby tissue or other places in the body. Monoclonal antibodies, such as
pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Imatinib
mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving pembrolizumab and imatinib mesylate may work better in treating patients with
melanoma with c-KIT mutation or amplification that has spread to nearby tissue or other
places in the body.